•
SV
SVRA
Savara Inc.
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
1.26B
Volume
1.35M
52W High
$7.01
52W Low
$1.89
Open
$0.00
Prev Close
$5.97
Day Range
0.00 - 0.00
About Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Latest News
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Benzinga•Dec 17
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Benzinga•Nov 20
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
Benzinga•Nov 7
SVRA DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA
GlobeNewswire Inc.•Nov 6
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Benzinga•Nov 3
SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA
GlobeNewswire Inc.•Nov 2
SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA
GlobeNewswire Inc.•Oct 30
DEADLINE ALERT for QMCO, TROX, SVRA, FLYE: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions
GlobeNewswire Inc.•Oct 30